Waste Management Inc. (NYSE: WM) topped analysts’ expectations for revenue and earnings in the second quarter of 2019. Shares were up 1.1% in morning hours on Thursday.
Total revenues rose nearly 6% year-over-year to $3.95 billion, surpassing estimates of $3.94 billion. Revenue growth was driven by strong yield and volume growth in the collection and disposal business.

Net income was $381 million, or $0.89 per share, compared to $499 million, or $1.15 per share, in the prior-year period. Adjusted net income was $470 million, or $1.11 per share. Analysts had forecast EPS of $1.08.
Total company internal revenue growth from volume, including the recycling business, was 4%. Collection and disposal business internal revenue growth from volume was 4.4%. Internal revenue growth from yield for the collection and disposal business was 2.7% versus 2.3% in the year-ago quarter. Core price was 5.4% compared to 5.3% last year.
During the quarter, the company saw a 4% revenue growth in its total collection business, helped by increases across all its divisions. The landfill business saw a 11% growth in revenue while the transfer business saw an 8% increase. The recycling business posted a 13% drop in revenue.
Despite an updated expectation for a full-year recycling headwind of $0.01-0.02 per share, the company is reaffirming its full-year 2019 guidance for adjusted EPS of $4.28-4.38. Adjusted operating EBITDA is expected to be $4.40 billion to $4.45 billion, and free cash flow is expected to be $2.025 billion to $2.075 billion.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q2 2024 earnings report
Shares of the J.M. Smucker Co. (NYSE: SJM) were up over 4% on Tuesday after the company reported its earnings results for the second quarter of 2024. Profits beat expectations
Nio reports Q3 2023 results. Here’s all you need to know
Electric car maker NIO Inc. (NYSE: NIO) reported a net loss for the third quarter of 2023, despite a sharp increase in revenues. The China-based company also provided its guidance
Ocean Biomedical’s breast cancer research uncovers new tumor suppression pathway for its proprietary antibody
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said that new findings, co-authored by the company’s scientific co-founder Jack A. Elias in the peer-reviewed journal Immunity, have revealed the